SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
作者信息
D'Silva Kristin M, Serling-Boyd Naomi, Hsu Tiffany Y-T, Sparks Jeffrey A, Wallace Zachary S
机构信息
Rheumatology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
出版信息
Ann Rheum Dis. 2021 Jun;80(6):817-819. doi: 10.1136/annrheumdis-2020-219808. Epub 2021 Jan 12.
Abstract
摘要
相似文献
1
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
Ann Rheum Dis. 2021 Jun;80(6):817-819. doi: 10.1136/annrheumdis-2020-219808. Epub 2021 Jan 12.
2
Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'.
Ann Rheum Dis. 2023 Jun;82(6):e130. doi: 10.1136/annrheumdis-2021-220148. Epub 2021 Mar 10.
3
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
4
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.
Ann Rheum Dis. 2022 Feb;81(2):289-291. doi: 10.1136/annrheumdis-2021-221326. Epub 2021 Sep 6.
5
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.
Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5.
6
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001332.
7
Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases.
Clin Exp Rheumatol. 2023 Mar;41(3):758-759. doi: 10.55563/clinexprheumatol/3pcfrz. Epub 2022 Oct 13.
8
Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient.
J Infect. 2020 Dec;81(6):979-997. doi: 10.1016/j.jinf.2020.05.043. Epub 2020 May 29.
9
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
10
SARS-CoV-2 seroprevalence in patients with autoimmune rheumatic diseases versus family controls: a multi-city cross-sectional survey.
Rheumatol Int. 2024 Jan;44(1):81-87. doi: 10.1007/s00296-023-05489-x. Epub 2023 Oct 31.
引用本文的文献
1
Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study.
Rheumatology (Oxford). 2024 Oct 1;63(10):2828-2837. doi: 10.1093/rheumatology/kead662.
2
Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases.
Sci Transl Med. 2023 Sep 6;15(712):eadf6598. doi: 10.1126/scitranslmed.adf6598.
3
Considerations for Pharmacologic Management of Rheumatoid Arthritis in the COVID-19 Era: a Narrative Review.
Curr Rheumatol Rep. 2023 Nov;25(11):236-245. doi: 10.1007/s11926-023-01111-y. Epub 2023 Aug 19.
4
Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019.
Rheum Dis Clin North Am. 2023 Aug;49(3):695-711. doi: 10.1016/j.rdc.2023.03.007. Epub 2023 Mar 14.
5
Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19.
medRxiv. 2022 Sep 26:2022.09.25.22280335. doi: 10.1101/2022.09.25.22280335.
6
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study.
Lancet Rheumatol. 2022 Sep;4(9):e614-e625. doi: 10.1016/S2665-9913(22)00191-6. Epub 2022 Aug 9.
7
Humoral and cellular response in convalescent COVID-19 lupus patients.
Sci Rep. 2022 Aug 12;12(1):13787. doi: 10.1038/s41598-022-17334-5.
8
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.
Ann Rheum Dis. 2022 Dec;81(12):1742-1749. doi: 10.1136/ard-2022-222954. Epub 2022 Aug 9.
9
Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal-A Multicenter, Nationwide Study.
Front Med (Lausanne). 2022 Jun 13;9:901817. doi: 10.3389/fmed.2022.901817. eCollection 2022.
10
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron.
medRxiv. 2022 Jun 20:2022.06.19.22276599. doi: 10.1101/2022.06.19.22276599.
本文引用的文献
1
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
N Engl J Med. 2021 Feb 11;384(6):533-540. doi: 10.1056/NEJMoa2034545. Epub 2020 Dec 23.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic.
Ann Rheum Dis. 2021 May;80(5):660-666. doi: 10.1136/annrheumdis-2020-219279. Epub 2020 Nov 30.
4
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.
5
Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19.
Cell. 2020 Oct 1;183(1):143-157.e13. doi: 10.1016/j.cell.2020.08.025. Epub 2020 Aug 19.
6
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
Zotero 插件